| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.012 | 0.8 |